Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 06, 2007. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding Ordinary Shares of the Company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a regulatory disclosure of share transactions and does not contain financial performance data.
Material Changes
The filing details specific share sales executed on February 27, 2007, by the Administrators of the SmithKline Beecham Employee Benefit Trust ("the Trust") on behalf of plan participants:
- Annual Investment Plan: 667 Ordinary shares sold at GBP 14.39 per share.
- Bonus Investment Plan: 1,013 Ordinary shares sold at GBP 14.39 per share.
These transactions were notified to the Company on March 05, 2007. The Trust is a discretionary fund for non-US employees and former employees. Director Mr. J S Heslop holds an interest in the fund consistent with other non-US employees.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the disclosure of the aforementioned share transactions in accordance with Disclosure Rule 3.1.4R(1)(b).
Investor Verification Points
- Confirm the total volume of shares sold (1,680 shares) and the execution price (GBP 14.39) for the SmithKline Beecham Employee Benefit Trust on February 27, 2007.
- Verify the notification timeline: transactions occurred on February 27, 2007, and were reported to the Company on March 05, 2007.
- Note that this filing does not reflect operational or financial performance for the period.